EU and US could reach trade deal this weekend - Reuters
AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its asthma treatment, Breztri Aerosphere, has met all primary endpoints in the Phase III KALOS and LOGOS trials. The trials demonstrated significant improvement in lung function compared to the standard dual-combination therapies for patients with uncontrolled asthma.
The KALOS and LOGOS studies were designed to evaluate the efficacy and safety of the triple-combination therapy, which includes budesonide, glycopyrronium, and formoterol fumarate. The trials involved around 4,400 patients and aimed to provide a more effective treatment option for those who remain uncontrolled on current dual therapies.
Asthma affects an estimated 262 million people globally, with nearly half of those treated with dual therapy still experiencing uncontrolled symptoms, which can severely impact their quality of life.
Professor Alberto Papi, the primary investigator of the trials, highlighted the significant number of patients who remain uncontrolled with current treatments and emphasized the potential of Breztri to change the standard of care for asthma.
Sharon Barr, AstraZeneca (NASDAQ:AZN)’s Executive Vice President of BioPharmaceuticals R&D, expressed excitement over the positive trial results and the potential for Breztri to improve the lives of millions of asthma patients. The company plans to share the full trial results with regulatory authorities and at an upcoming medical meeting.
Breztri is already approved in over 80 countries, including the US, EU, China, and Japan, for the treatment of chronic obstructive pulmonary disease (COPD) and was prescribed to over 5.5 million patients in 2024.
The safety and tolerability profile of Breztri remained consistent with no new signals identified in the KALOS or LOGOS trials.
This news is based on a press release statement and provides a promising outlook for asthma patients seeking more effective treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.